All In Biotech

Drug Trial Radar · NCT01236144

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

An NCRI Acute Myeloid Leukaemia Working Group Pilot Trial Under the Auspices of the Cardiff Experimental Cancer Medicine Centre to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

Last checked: Nov 20, 2026Latest source record: Jun 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Apr 2011

Primary completion

Dec 2013

Study completion Jan 2014

Sponsor

Lead sponsor
Cardiff UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Leukaemia & Lymphoma Research Group; Experimental Cancer Medicine Centres
First posted
Nov 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AML18 Pilot Trial will evaluate the feasibility of three interventions that are planned to be included in the forthcoming NCRI AML18 Trial. One intervention will be to evaluate combining the Tyrosine Kinase Inhibitor AC220 with three courses of standard DAE (Daunorubicin, Ara-C, Etoposide). AC220 will be given following each treatment course, daily by mouth for 7, 14 or 21 days. AC220 will be evaluated at 3 dose levels of 60, 90 and 135 mg flat dose. A 4th dose level of 40 mg will be introduced should patients not respond well to 60 mg. The second intervention to be tested is the combination of the CXCR4 inhibitor Plerixafor with up to three courses of the chemotherapy combination of DClo (Daunorubicin, Clofarabine). Patients/investigators will be able to choose which intervention to enter. Depending on recruitment requirements, only one intervention might be available at any one time. The third intervention Patients will receive 3 treatments of 100 mg of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.

Conditions

  • Acute Myeloid Leukaemia
  • High Risk Myelodysplastic Syndrome

Interventions

  • PlerixaforDrug

    Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.

  • AC220Drug

    Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.

  • GanetespibDrug

    Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response (CR, CRi, PR) achievement, and reasons for failureTime frame: Duration of treatment
  2. MortalityTime frame: At 30 days and 8 weeks
  3. Toxicity (haematological and non-haematological)Time frame: Duration of trial treatment
  4. SurvivalTime frame: At 6 and 12 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom

  • Belfast City Hospital

    Belfast, United Kingdom

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • University Hospital of Wales

    Cardiff, United Kingdom

  • Castle Hill Hospital

    Hull, United Kingdom

  • St James's University Hospital

    Leeds, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • St Bartholomew's Hospital

    London, United Kingdom

  • Christie Hospital

    Manchester, United Kingdom

  • Manchester Royal Infirmary

    Manchester, United Kingdom

  • Freeman Hospital

    Newcastle, United Kingdom

  • Nottingham University Hospital

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.